TRCT
KPTI icon

Tower Research Capital (TRC)’s Karyopharm Therapeutics KPTI Stock Holding History

Tower Research Capital (TRC)’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,089
Closed -$7.12K – 5404
2025
Q3 		$7.12K Buy
1,089
+239
+28% +$1.29K ﹤0.01% 4116
2025
Q2 		$3.66K Buy
+850
New +$4.17K ﹤0.01% 4452
2025
Q1 		– Sell
-513
Closed -$5.2K – 5524
2024
Q4 		$5.2K Buy
+513
New +$6.2K ﹤0.01% 4334
2024
Q3 		– Sell
-2,346
Closed -$30.5K – 5872
2024
Q2 		$30.5K Buy
2,346
+2,237
+2,052% +$37K ﹤0.01% 3479
2024
Q1 		$2.47K Sell
109
-665
-86% -$11.7K ﹤0.01% 5033
2023
Q4 		$10K Sell
774
-702
-48% -$9.46K ﹤0.01% 4304
2023
Q3 		$29.7K Buy
1,476
+312
+27% +$7K ﹤0.01% 3037
2023
Q2 		$31.3K Sell
1,164
-126
-10% -$5.43K ﹤0.01% 2983
2023
Q1 		$75K Sell
1,290
-51
-4% -$2.52K ﹤0.01% 2134
2022
Q4 		$69K Sell
1,341
-952
-42% -$66K ﹤0.01% 2122
2022
Q3 		$188K Buy
2,293
+353
+18% +$26.4K ﹤0.01% 1998
2022
Q2 		$131K Buy
1,940
+1,505
+346% +$138K ﹤0.01% 2084
2022
Q1 		$48K Sell
435
-881
-67% -$110K ﹤0.01% 2766
2021
Q4 		$127K Sell
1,316
-417
-24% -$41.6K ﹤0.01% 2073
2021
Q3 		$152K Buy
1,733
+1,375
+384% +$143K ﹤0.01% 2061
2021
Q2 		$55K Sell
358
-1,644
-82% -$239K ﹤0.01% 2950
2021
Q1 		$316K Sell
2,002
-174
-8% -$36.7K 0.01% 1631
2020
Q4 		$505K Buy
2,176
+1,756
+418% +$407K 0.02% 986
2020
Q3 		$92K Sell
420
-401
-49% -$98.1K ﹤0.01% 3208
2020
Q2 		$233K Buy
+821
New +$243K 0.01% 1658
2020
Q1 		– Sell
-310
Closed -$89K – 3502
2019
Q4 		$89K Buy
310
+78
+34% +$16.9K 0.01% 1001
2019
Q3 		$34K Buy
232
+196
+544% +$26.6K ﹤0.01% 2068
2019
Q2 		$3K Sell
36
-1
-3% -$80 ﹤0.01% 3144
2019
Q1 		$3K Buy
37
+24
+185% +$2.66K ﹤0.01% 3296
2018
Q4 		$2K Sell
13
-13
-50% -$2.19K ﹤0.01% 3380
2018
Q3 		$7K Sell
26
-93
-78% -$25.7K ﹤0.01% 2962
2018
Q2 		$30K Buy
+119
New +$29.4K ﹤0.01% 2172
2018
Q1 		– Sell
-60
Closed -$9K – 3570
2017
Q4 		$9K Sell
60
-459
-88% -$73.7K ﹤0.01% 2616
2017
Q3 		$86K Buy
+519
New +$74.3K 0.01% 1508
2017
Q1 		– Sell
-165
Closed -$23K – 3507
2016
Q4 		$23K Sell
165
-69
-29% -$9.33K ﹤0.01% 2013
2016
Q3 		$34K Sell
234
-43
-16% -$5.17K ﹤0.01% 1341
2016
Q2 		$28K Buy
277
+218
+369% +$28.3K ﹤0.01% 1975
2016
Q1 		$8K Buy
+59
New +$6.51K ﹤0.01% 2208
2015
Q4 		– Sell
-628
Closed -$99K – 4783
2015
Q3 		$99K Buy
628
+517
+466% +$138K 0.01% 572
2015
Q2 		$45K Sell
111
-70
-39% -$30.3K ﹤0.01% 1452
2015
Q1 		$83K Buy
181
+174
+2,486% +$75K 0.01% 1047
2014
Q4 		$4K Sell
7
-61
-90% -$34.6K ﹤0.01% 2874
2014
Q3 		$36K Buy
+68
New +$38.4K ﹤0.01% 1817
2014
Q2 		– Sell
-9
Closed -$4.19K – 4357
2014
Q1 		$4K Sell
9
-15
-63% -$7.6K ﹤0.01% 3438
2013
Q4 		$9K Buy
+24
New +$6.63K ﹤0.01% 3086

Other funds holding KPTI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
EAM
Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Tower Research Capital (TRC)'s KPTI Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of Karyopharm Therapeutics (KPTI) in Q4 2025, closing a stake of 1,089 shares — an estimated $7.12K sold.

Tower Research Capital (TRC) first reported a position in KPTI in Q4 2013 and held it in 40 quarters. The position peaked at $505K in Q4 2020. 69 funds tracked by Wall St. Rank hold KPTI as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining Karyopharm Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,089 Karyopharm Therapeutics shares in Q4 2025, an estimated $7.12K.
  • Tower Research Capital (TRC) first reported a position in Karyopharm Therapeutics in Q4 2013 and held it in 40 quarters.
  • Tower Research Capital (TRC)'s Karyopharm Therapeutics position peaked at $505K in Q4 2020.
  • 69 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.